Search results
Author(s):
Dyah Wulan Anggrahini
,
Detty Siti Nurdiati
,
Anggoro Budi Hartopo
,
et al
Added:
2 months ago
Author(s):
Kazuya Hosokawa
,
Abe Kotaro
Added:
2 years ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3…
View more
Author(s):
Burhanuddin Moize
,
Raja Ezman Raja Shariff
,
Mohd Rahal Yusoff
,
et al
Added:
1 year ago
Vineet Agrawal
Job title: Assistant Professor of Medicine
Author
Author(s):
Harriette Van Spall
,
Luke Laffin
Added:
9 months ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial…
View more
John G Coghlan
Job title: Director of the National Pulmonary Hypertension Service
Author
Vallerie V McLaughlin
Job title: Associate Professor
Author
Robert P Frantz
Job title: Assistant Professor of Medicine and Director of the Pulmonary Hypertension Clinic
Author
Maurice Beghetti
Job title: Head of the Paediatric Cardiology Unit
Author
Author(s):
Geetha Kandavello
Added:
3 months ago